Corrigendum: Clinical presentation and prognosis in MOG-antibody disease: A UK study (Brain (2017) 140 12 DOI: 10.1093/brain/awx276);Clinical presentation and prognosis in MOG-antibody disease: A UK study

Brain

Volumn 140, Issue 12, 2017, Pages 3128-3138

  Jurynczyk, Maciej ^a   Messina, Silvia ^a   Woodhall, Mark R ^a   Raza, Naheed ^a   Everett, Rosie ^a   Roca Fernandez, Adriana ^a   Tackley, George ^a   Hamid, Shahd ^a   Sheard, Angela ^b   Reynolds, Gavin ^a   Chandratre, Saleel ^a   Hemingway, Cheryl ^c   Jacob, Anu ^b   Vincent, Angela ^a   Leite, M Isabel ^a   Waters, Patrick ^a   Palace, Jacqueline ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

acute disseminated encephalomyelitis; demyelination; multiple sclerosis; neuroinflammation; neuromyelitis optica

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; AUTOANTIBODY; MOG PROTEIN, HUMAN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; DISABILITY; DISEASE COURSE; DISEASE DURATION; ERECTILE DYSFUNCTION; EYE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MOG ANTIBODY DISEASE; MYELITIS; ONSET AGE; OPTIC NEURITIS; PRIORITY JOURNAL; PROGNOSIS; RACISM; RELAPSE; SEX DIFFERENCE; UNITED KINGDOM; VISUAL ACUITY; ADOLESCENT; AGED; BLOOD; CHILD; DISABLED PERSON; INFANT; MIDDLE AGED; MYELOOPTIC NEUROPATHY; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISABLED PERSONS; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA; PROGNOSIS; UNITED KINGDOM; YOUNG ADULT;

EID: 85040046367     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awy014     Document Type: Erratum

References (23)

1. Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease [Internet]. Ann Neurol 2009; 66: 833-42.
2. Hacohen Y, Absoud M, Deiva K, Hemingway C, Nytrova P, Woodhall M, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children [Internet]. Neurol Neuroimmunol Neuroinflamm 2015; 2: e81.
3. Hoftberger R, Sepulveda M, Armangue T, Blanco Y, Rostasy K, Calvo AC, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease [Internet]. Mult Scler J 2015; 21: 866-74.
4. Hyun J-W, Woodhall MR, Kim S-H, Jeong IH, Kong B, Kim G, et al. Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases. J Neurol Neurosurg Psychiatry 2017; 88: 811-17.
5. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J. Neuroinflammation 2016a; 13: 279.
6. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016b; 13: 280.
7. Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain 2017; 140: 617-27.
8. Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015; 2: e163.
9. Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the UK and Japan. Brain 2012a; 135: 1834-49.
10. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 1-8.
11. Kitley J, Woodhall M, Waters P, Leite MI, Devenney E, Craig J, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012b; 79: 1273-7.
12. Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler J 2013; 19: 1261-7.
13. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflamm 2011; 8: 184.
14. Miller H, Simpson CA, Yeates WK. Bladder dysfunction in multiple sclerosis. BMJ 1965; 1: 1265-9.
15. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen J a, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
16. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9: 455-61.
17. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, Jorge FMDH, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474-81.
18. Sepulveda M, Armangue T, Martinez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes [Internet]. J Neurol 2016; 263: 1349-60.
19. Spadaro M, Gerdes LA, Krumbholz M, Ertl-Wagner B, Thaler FS, Schuh E, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis [Internet]. Neurol Neuroimmunol Neuroinflamm 2016; 3: e257.
20. Waters P, Woodhall M, O'Connor KC, Reindl M, Lang B, Sato DK, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015; 2: e89.
21. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177.
22. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica [Internet]. Lancet Neurol 2007; 6: 805-15.
23. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-9.